JYNT stock forecast, quote, news & analysis
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States... Show more
Why The Joint Corp. (JYNT) Stock Is Down -13.5% in the Last 30 Days
Key Takeaways
- JYNT shares have declined roughly 13.5% over the past 30 days, from about $8.44 to around $7.30.
- The slide extends a broader multi-month downtrend even as the company completes its "Joint 2.0" shift into a pure-play franchisor.
- Persistent top-line softness has weighed on sentiment: system-wide sales fell 3.7% year over year in Q2 2026, and Q1 comparable sales were down 4.2%.
- Management lowered its 2026 new-clinic-opening guidance to 22–26 locations, down from a prior range of 30–35.
- Improving profitability and ongoing share repurchases have not yet reversed the share-price decline.
The Joint Corp. (JYNT) Company Overview and Market Position
The Joint Corp. is the nation's largest operator, manager, and franchisor of chiropractic clinics through The Joint Chiropractic network. The company pioneered a retail healthcare model built around walk-in visits, affordable membership plans, and no insurance requirement, making routine chiropractic care more accessible than traditional practices.
Headquartered in Scottsdale, Arizona, The Joint operates more than 940 locations nationwide and reports over 14 million patient visits annually. Its franchise-based model generates revenue primarily through royalties and fees rather than clinic operations, a structure the company has been actively simplifying through its "Joint 2.0" refranchising initiative. Investors follow the stock for its asset-light business model, consumer wellness exposure, and capital-allocation initiatives such as share buybacks.
The Joint Corp. (JYNT) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, JYNT has fallen from a closing price of approximately $8.44 to about $7.30, a decline of roughly 13.5%. The shares have trended lower through much of that period, with a brief rebound in mid-September giving way to renewed selling pressure into October.
The quarterly picture tells a similar story. In late July, JYNT traded near $8.57; at approximately $7.30 the stock is down about 15% over the trailing quarter. The downtrend has been gradual rather than driven by a single sharp catalyst, reflecting a market reassessment of the company's near-term growth trajectory even as its operational transformation advances.
What Drove JYNT Stock Price in the Last 30 Days
No single company-specific event fully explains the recent slide; instead, JYNT has drifted lower amid persistent top-line softness. The company's second-quarter 2026 results, reported in early August, showed a 14% year-over-year increase in revenue to $15.2 million and improved profitability, but system-wide sales declined 3.7% year over year to $128 million, underscoring pressure on the underlying clinic network.
Management has cited cost-of-living pressures as a headwind to membership growth, with comparable sales remaining negative. The company also lowered its full-year new-clinic-opening guidance to 22–26 locations from 30–35, signaling a slower near-term expansion pace. Higher selling and marketing expenses, up 40% year over year in Q2, have added near-term margin considerations.
Positive developments, including the October reacquisition of regional developer rights across Texas and other markets, have not been enough to lift the shares in the short term. The combination of softer system-wide sales and reduced opening guidance has kept investor sentiment cautious.
What Drove JYNT Stock Performance Over the Last Quarter
Over the past quarter, JYNT's performance has been shaped by the final stages of its transformation into a pure-play franchisor. The company signed an agreement to sell 45 company-owned clinics in Southern California to Elite Chiro Group for approximately $2.3 million, effectively completing the "Joint 2.0" refranchising effort and reducing corporate-owned clinics to just three of roughly 940 locations.
This strategic shift has meaningfully improved profitability. Adjusted EBITDA from continuing operations reached $1.5 million in Q2 2026, up from $88,000 a year earlier, and free cash flow improved. The company has also continued repurchasing shares and reacquiring regional developer territories to capture a larger share of long-term royalty economics.
Despite these structural improvements, the shares have lagged because system-wide sales and comparable-store trends remain negative, and investors are weighing a slower clinic-opening cadence against the promise of higher margins from the refranchised model.
Trending AI Robots
For traders seeking a systematic, data-driven complement to fundamental analysis, Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots. Tickeron offers hundreds of AI trading bots that trade thousands of tickers, but only the top-performing and most relevant bots appear in this section. These bots vary in strategy, timeframe, and performance metrics, allowing users to explore approaches that match different risk tolerances and holding periods. The page provides a useful starting point for those interested in how algorithmic strategies track market conditions.
JYNT Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the key variable for JYNT is whether comparable-sales trends inflect as management has guided. The company expects comps to improve through the back half of 2026 as national marketing matures, pricing optimization rolls out across more clinics, and patient retention initiatives take hold. Pricing increases of $5–$10 have been implemented across roughly 300 clinics, with the remainder following.
Investors should also monitor new clinic openings and net clinic count, progress on the refranchising completion and its impact on margins, and continued capital-allocation activity including share repurchases. Broader consumer discretionary spending on wellness and chiropractic care, along with initiatives such as B2B partnerships and the CareCredit rollout, will influence demand. The company's next quarterly earnings report will be a key checkpoint for whether profitability gains can offset persistent top-line pressure.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
JYNT's Indicator enters downward trend
The Aroon Indicator for JYNT entered a downward trend on October 23, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 310 similar instances where the Aroon Indicator formed such a pattern. In 258 of the 310 cases the stock moved lower. This puts the odds of a downward move at 83%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 45 cases where JYNT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JYNT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where JYNT's RSI Indicator exited the oversold zone, 31 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JYNT as a result. In 78 of 107 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for JYNT just turned positive on October 19, 2026. Looking at past instances where JYNT's MACD turned positive, the stock continued to rise in 31 of 43 cases over the following month. The odds of a continued upward trend are 72%.
Following a +2.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where JYNT advanced for three days, in 158 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
JYNT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.273) is normal, around the industry mean (204.120). P/E Ratio (27.038) is within average values for comparable stocks, (19.084). Projected Growth (PEG Ratio) (0.140) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.091) among similar stocks. P/S Ratio (2.154) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. JYNT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JYNT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an operator of chiropractic care clinics
Industry HospitalNursingManagement